Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib plus gefitinib in EGFR-mutant non-squamous NSCLC
CTR20161072Phase 2Completed
- Sponsor
- HUTCHMED
- Start
- Jan 2017
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fruquintinib, gefitinib in Non-small cell lung cancer (NS-NSCLC), sponsored by HUTCHMED. Started Jan 2017; status: completed.
02
Drugs
fruquintinibgefitinib
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on CTR20161072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20161072.